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Plasmodiuma b s t r a c t
The enoyl acyl-carrier protein reductase (ENR) enzyme is harbored within the apicoplast of apicomplexan
parasites providing a signiﬁcant challenge for drug delivery, which may be overcome through the addi-
tion of transductive peptides, which facilitates crossing the apicoplast membranes. The binding site of tri-
closan, a potent ENR inhibitor, is occluded from the solvent making the attachment of these linkers
challenging. Herein, we have produced 3 new triclosan analogs with bulky A- and B-ring motifs, which
protrude into the solvent allowing for the future attachment of molecular transporters for delivery.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.The Toxoplasma gondii (T. gondii) parasite and other apicomplex-
ans rely on the fatty acid synthesis type II pathway (FAS II), which is
prokaryotic-like and distinct from the eukaryotic fatty acid type I
pathway (FAS I). FAS II is carried out by discrete mono-functional
enzymes, whereas FAS I is typically carried out by one large poly-
peptide complex.1,2 This distinction hasmade this pathway a prom-
ising target for anti-microbial drug design.3,4 The FAS II pathway is
composed of four enzymes in an iterative process of fatty acid elon-
gation, in which the enoyl acyl-carrier protein reductase (ENR) has
gained the most attention with a range of drugs developed against
it. These include the anti-tuberculosis drug isoniazid, the diazabo-
rine family and triclosan which is a common antimicrobial found
in, amongst other things, toothpastes, mouthwashes and chopping
boards.5–8 Triclosan has been shown to be a very potent inhibitorwhich binds at the core of the ENR enzyme,makingp stacking inter-
actionswith the reduced NAD+ cofactor.9 Its bindingmode has been
characterized as a two state process, where it primarily interacts
with the NAD+ cofactor followed by an a-helix packing over the tri-
closan, burying it away from the solvent forming a slow tight bind-
ing complex.10 Triclosan is a relatively simple scaffold which has
been extensivelymodiﬁed by a number of groups to improve its AD-
MET properties.
Signiﬁcant progress has been made toward the development of
both T. gondii and Plasmodium falciparum medicines through the
discovery of a FAS II pathway residing within their apicoplast.11,12
This was particularly pertinent when it was discovered that the P.
falciparum, Eimeria tenella and T. gondii ENR enzyme could be
inhibited by the potent antibacterial triclosan.13–15 Since this dis-
covery, a number of groups have developed a range of triclosan
analogs which have shown potent inhibitory effects often with im-
proved ADMET properties.16–21 Although studies have reported
that FASII is not essential for blood stage survival of P. falciparum
it does play an important role in liver-stage development. More-
over, triclosan may have an off target effect within the blood stage
of its lifecycle.22,23
A signiﬁcant problem with these inhibitors is the need to cross
several membranes imposed by the host cell, parasite and
Scheme 1. Synthesis of triclosan analogs bearing isoxazole group on ring B. Reagents and conditions: (a) 3-chloro-4-ﬂuorobenzaldehyde, Cs2CO3, DMF, 95 C, 16 h, 72%; (b)
H2O–EtOH–ice (1:1:2), H2NOHHCl, 50% aq NaOH, rt, 1.5 h, 79%; (c) NCS, DMF, rt, 1.5 h, 100%; (d) sodium ascorbate, CuSO45H2O, KHCO3, 1-alkyne, t-BuOH–H2O (1:1), rt, 1 h.
For 4, R = CH2CH2OTBDPS, 51%; for 5, R = n-Pr, 50%; (e) for 6: CH2Cl2, BBr3 (4.0 equiv), 78 C to rt, 3 h, 35%. For 7: CH2Cl2, BBr3 (8.0 equiv), 78 C to rt, overnight, 61%.
Scheme 2. Synthesis of triclosan analogs bearing isoxazole groups on ring A and B. Reagents and conditions: (a) (1) LiAlH4, Et2O, 78 C to 0 C, 2.5 h, (2) H2O, 1.0 M NaOH,
50%; (b) 5-methylisoxazole-3-carboxylic acid, CH2Cl2, HOBt, EDCI, Et3N, rt, 17 h then H2O, 100% of crude material; (c) CH2Cl2, BBr3 (8.0 equiv), 78 C to rt within 1 h, then rt
for 5 h, 32%.
3552 S. P. Muench et al. / Bioorg. Med. Chem. Lett. 23 (2013) 3551–3555apicoplast in order to reach the ENR enzyme target. This has been
aided with some success through the addition of a cleavable linker
and transductive peptide, although further work in this area is
needed.24 In order to establish if a more stable, non releasable
molecular transporter can be attached to the A- or B-ring of triclo-
san in a way that does not signiﬁcantly alter binding to ENR, weTable 1
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a Toxicity to human foreskin ﬁbroblasts.
b At compound concentration (lM), enzyme inhibition percentage (%).have taken two of our previously successful triclosan modiﬁcations
which resulted in extensions on the A- and B- ring and combined
them. In particular, isoxazole groups were chosen since they
retained good potency whilst improving the physiochemical prop-
erties (Stec et al., in press). This has resulted in a set of three com-
pounds with potent inhibitory effects and isoxazole extensions,allenge TgENR Enzyme assay P. falciparum blood stage
dose response (ng/ml)
citya (lM) Conc. b(lM) /Inhibition (%) IC50 (nM) D6 TM91C235
98 15 N/A N/A
1/94 29 >2443 >N/A
1/94 34 >10,000 >10,000
1/89 137 >10,000 >10,000
Figure 2. Structural formula of compound 33.
S. P. Muench et al. / Bioorg. Med. Chem. Lett. 23 (2013) 3551–3555 3553which allow through the incorporation of functional groups to be
further utilized for the addition of a linker and transductive pep-
tide or a non-releaseable linker.
The compounds were generated by reacting 4-hydroxy-3-
methoxybenzonitrile with 3-chloro-4-ﬂuorobenzaldehyde to give
intermediate 1, which was readily converted to the imidoyl chlo-
ride 3 in a two-step protocol.25 Subsequent reaction of 3 with
TBDPS protected 3-butyn-1-ol and 1-pentyne afforded the corre-
sponding isoxazoles 4 and 5.26 The ﬁnal compounds, 6 and 7, were
prepared by the modiﬁed demethylation procedure27 with BBr3,
employing 4 and 5 as the starting materials (Scheme 1).
Reduction of the nitrile 5 provided amine intermediate 8, which
was further elaborated through amide bond formation with 5-
methylisoxazole-3-carboxylic acid and demethylation to give the
ﬁnal product 10 (Scheme 2).28 Full details on compound synthesis
are in the Supplementary data.
Inhibitory assays for parasite replication, toxicity against ﬁbro-
blast host cell tests methods, and enzyme assays were performed
as previously described (Stec et al., in press).21,29–32
A major hurdle in targeting pathways which reside within the
apicoplast is the need for the inhibitor to cross several membrane
barriers. In order to avoid this difﬁculty, we adapted the triclosan
scaffold to contain bulky substituents on both the A- and B-rings
that were amenable to the addition of non-releasable transport
peptides ((Table 1) (Fig. 1A)). The relatively small binding pocket
means that these non-releasable linkers must sit outside the cav-Figure 1. (A) Overlay of triclosan and 10 within the ENR active site showing the similar
yellow (10) or magenta (triclosan) for oxygen, nitrogen, chlorine and carbon, respectively
protruding into the solvent. (C) Modeling of 10 within the TgENR/NAD+/triclosan cryst
Modeling of 10 within the modiﬁed TgENR crystal structure where Phe241 has adoptedity, exposed to the solvent to avoid any steric hindrance upon
inhibitor binding.
In the ﬁrst instance, we used a previously identiﬁed modiﬁca-
tion on the triclosan B-ring whereby a substituted-isoxazole group
was added at the 40-position.32 This group makes favorable interac-
tions around the entrance of the triclosan binding site and extends
out towards the solvent.
In order to test whether further modiﬁcations could be placed
at the exit of the binding site, the substituent on the isoxazole ring
was replaced with either a 5-propyl or 5-ethyl alcohol group.
Although only a minimal improvement in the MIC50; from 10 lM
to 4 lM (6) and 7.5 lM (7) is seen, no detrimental effect to the
enzymatic activity is observed. Importantly, docking studies have
shown that both of these extensions can clearly protrude from
the hydrophobic binding site towards a more solvent exposed area
of the enzyme (Fig. 1B). Further structural modiﬁcation of the isox-
azole ring could allow for conjugation to a delivery peptide via
either a releasable or non-releasable linker.mode of binding for the common A and B-ring motifs, colored red, blue, green and
. (B) Surface view of the modeled TgENR/NAD+/10 structure with the modiﬁed B-ring
al structure where Phe241 adopts a ‘closed’ position causing steric hindrance. (D)
an ‘open’ position exposing the A-ring to the solvent.
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iﬁcation on the A-ring of triclosan, which occupies an enclosed
hydrophobic region, resulting in its exposure to the outside solvent
thus allowing for its attachment to a delivery peptide. This is due
to the A-ring of triclosan being buried within the binding site,
whereas the B-ring is at the base of a channel which leads to the
solvent. The tight packing about the A-ring within the ENR enzyme
binding site often makes modiﬁcations about this ring difﬁcult as
there are several residues predicted to make steric clashes with
these modiﬁed structures, as seen in docking simulations. It is
important to note however that most modeling programs do not
account for protein ﬂexibility within the binding site.33
A solution to this problem was suggested through previous
studies of compound 33 (Fig. 2 (Stec et al., in press)). This com-
pound was predicted to bind in a reverse mode to that of triclosan,Figure 3. Efﬁcacy and absence of toxicity of compounds against T. gondii tachyzo-
ites. (A) Growth of RH-YFP in human Foreskin ﬁbroblasts (HFF), measured as
ﬂuorescence intensity. HFF infected with RH-YFP tachyzoites and ﬂuorescence
intensities were measured after 72 h. Non infected ﬁbroblasts that provided a
baseline control, HFF cells infected with 3200 RH-YFP tachyzoites treated with
pyrimethamine/sulfadiazine (p/s) or 0.1% DMSO serve as positive and negative
controls respectively. (B) Inhibitory effect of the compounds on RH-YFP. HFF cells
were infected with 3200 RH-YFP tachyzoites, compounds at various concentrations
were added 1 h after infection. The ﬂuorescence intensities of the samples as
reﬂecting numbers of parasites were measured 72 h after addition of compounds.
(C) Effect of the compounds on HFF viability. The viability of host HFF cells was
assessed by Wst-1 staining, after 72 h of incubation of compounds at 10 mM
concentration. Effect of various concentrations of DMSO present in the HFF culture
medium shows varying amounts of toxicity.that is, the A-ring would take the position of the B-ring and vice
versa, by the FLEXX docking program. This altered pose was observed
due to the large substituent on the A-ring causing severe steric
clashes within the binding site which could only be relieved
through the reverse binding mode. However, by allowing for ﬂex-
ibility within the active site, in particular the movement of Phe243
about Cb within the TgENR/NAD+ complex using the Swiss PDB
Viewer the original binding mode was seen.34 Those orientations
that could accommodate the greater steric bulk of our hybrid com-
pounds resulted in a more open binding site such that the A-ring
modiﬁcation is now exposed to the exterior solvent (Fig. 1C and
D). We have previously seen the movement of Phe243 about the
Cb, in a manner similar to that of the modeling in a TgENR co-crys-
tal structure for a different family of inhibitors (data not shown).
Subsequent docking of the compound series was carried out using
AUTODOCK 4.235 or MACROMODEL version 8.136 and PDB IDs 2O2S20 and
1LX637 available from the RCSB Protein DataBank.
A hybrid triclosan scaffold was then designed which contained
both A and B ringmodiﬁcations allowing for the compound to be ex-
posed to the solvent on both ends of the molecular scaffold (10).
Modeling studies for this compound with increased bulk on both
the A- and B-rings does not permit the reverse mode binding seen
for the compound 33, but instead adopts the position shown in Fig-
ure 1. Importantly, this compound, despite its bulkier nature,
showed no decrease inMIC50 value but a slight increase in IC50 value
from 29 nM (6) and 19 nM (compound 33) to 137 nM (10). This in-
crease in IC50 to 137 nM is still therapeutically viable and more
importantly, themodiﬁcations to both the A and B-ring has resulted
in a compound which is amenable to further structural modiﬁca-
tions to improve both binding and delivery via releasable/non-
releasable trans-peptide linkers. In vitro cytotoxicity tests also
showed no noticeable increase in toxicity based on the assay used.
Growth was measured using a type 1 T. gondii parasite tachyzoite
RH stably transfected with the yellow ﬂuorescent protein (RH-YFP)
gene,with the relative ﬂuorescence intensities of the parasites being
directly correlated with parasite viability and numbers (Fig. 3).
The activity of the 3 compounds (6, 7 and 10) were also tested
against two different strains of P. falciparum (D6 & TM91C235) in a
dose-response growth inhibition assay. Only 6 showed modest
activity against the drug sensitive strain, D6, but no activity against
the drug resistant strain, TM91C235 (Table 1). It is likely that the
non-essential nature of the FASII pathway within the blood stage
of the P. falciparum is responsible for the poor inhibitory effect of
these compounds within our assay.22 Further work will determine
the potency of these inhibitors against the liver stage parasite
which would be important in stopping recrudescence of the Plas-
modium parasite.
These results have shown how the triclosan scaffold can be
modiﬁed to result in both the A- and B-rings being exposed to
the exterior solvent without a signiﬁcant loss in potency or detect-
able increase in toxicity. This is important since it allows for fur-
ther structural modiﬁcations to be made which are not
constrained by the size of the binding site. This also allows for
the addition of chemical functionalities which may aid in the deliv-
ery of triclosan into the apicoplast, a signiﬁcant problem in current
drug design. Moreover, the bradyzoite form of T. gondii is currently
impossible to treat with current therapeutics due to the barriers
put in place by the cyst form of the parasite. Further work will
be carried out to use this scaffold as a basis for modiﬁcations by
various linker elements which may aid in drug delivery and target-
ing of a compound whose potency is in the nanomolar range.
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